Printer Friendly

PainReform wins US FDA's approval for Phase III post-operative pain relief study of PRF-110.

M2 PHARMA-July 19, 2018-PainReform wins US FDA's approval for Phase III post-operative pain relief study of PRF-110

(C)2018 M2 COMMUNICATIONS

Pharmaceutical company PainReform Ltd reported on Wednesday the receipt of approval from the US FDA to launch two pivotal Phase III clinical trials of of PRF-110 for post-operative pain relief in soft and hard tissue.

Headquartered in Herzliya, Israel, the company is currently raising USD15m to conduct the trials.

The company said PRF-110 is an extended release version of ropivacaine providing longer relief of post-surgical incision pain. PRF-110 has the complete set of attributes, including efficacy, safety, physical properties and low-cost, to position it as the leading candidate in this very large pain relief drug market. The estimated market potential for pain relief drugs is USD5bn.

Both the pivotal Phase III clinical trials will use the company's PRF-110, a proprietary extended release version of ropivacaine (Naropin) that provides long relief of post-surgical incision pain.

Under a prior Phase II study, PRF-110 demonstrated pain relief for up to 72 hours, which is ten times longer than the current standard of care, concluded the company.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 19, 2018
Words:195
Previous Article:Nuevolution reports exercise of opt-in right by Amgen in first programme from multiple target research collaboration.
Next Article:eviCore healthcare announces St. Louis as its new service centre of healthcare providers.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters